Stanley Jack L, Mogford Daniel V, Lawrence Rebecca J, Lawrie Stephen M
Undergraduate-5th year, University of Edinburgh, Edinburgh, UK.
Department of Psychiatry, NHS Lothian, Edinburgh, UK.
BMJ Open. 2016 May 10;6(5):e009430. doi: 10.1136/bmjopen-2015-009430.
Non-illicit alternatives to controlled drugs, known as novel psychoactive substances (NPS), have recently risen to prominence. They are readily available, with uncertain pharmacology and no widely available assay. Given that psychiatric patients are at risk of comorbid substance abuse, we hypothesised that NPS use would be present in the psychiatric population, and sought to determine its prevalence and investigate the characteristics of those who use these drugs with a retrospective review of discharge letters.
General adult inpatient wards of a psychiatric hospital in a Scottish city.
All adult inpatients (18-65) discharged from general psychiatric wards between 1 July 2014 and 31 December 2014. Of the 483 admissions identified, 46 were admissions for maintenance electroconvulsive therapy (ECT) and were excluded. Of the remaining 437 admissions, 49 discharge letters were unobtainable, leaving 388 admissions to analyse.
The mention, or lack thereof, of NPS use in discharge letters was our planned primary outcome measure and was also the primary outcome measure we used in our analysis.
NPS use was identified in 22.2% of admissions, contributing to psychiatric symptoms in 59.3%. In comparison to non-users, NPS users were younger (p<0.01), male and more likely to have a forensic history ((p<0.001) for both). The diagnosis of drug-induced psychosis was significantly more likely in NPS users (p<0.001, OR 18.7, 95% CI 8.1 to 43.0) and the diagnosis of depression was significantly less likely (p<0.005, OR 0.133, CI 0.031 to 0.558). Use of cannabis was significantly more likely in NPS users (p<0.001, OR 4.2, CI 2.5 to 7.1), as was substitute opiate prescribing (p<0.001, OR 3.7, CI 1.8 to 7.4).
NPS use was prevalent among young, male psychiatric inpatients, in particular those with drug-induced psychosis and often occurred alongside illicit drug use.
被称为新型精神活性物质(NPS)的管制药物的非非法替代品近来日益突出。它们很容易获得,药理学特性不确定且没有广泛可用的检测方法。鉴于精神科患者存在合并物质滥用的风险,我们推测精神科人群中会存在使用NPS的情况,并试图通过回顾出院小结来确定其患病率,并调查使用这些药物者的特征。
苏格兰一座城市的一家精神病院的普通成人住院病房。
2014年7月1日至2014年12月31日期间从普通精神科病房出院的所有成年住院患者(18 - 65岁)。在确定的483例入院患者中,46例是进行维持性电休克治疗(ECT)的患者,被排除在外。在其余437例入院患者中,49份出院小结无法获取,剩余388例入院患者用于分析。
出院小结中提及或未提及使用NPS是我们计划的主要结局指标,也是我们分析中使用的主要结局指标。
在22.2%的入院患者中发现使用了NPS,其中59.3%的患者出现了精神症状。与未使用者相比,NPS使用者更年轻(p<0.01),多为男性,且更有可能有法医鉴定史(两者p<均0.001)。NPS使用者中药物性精神病的诊断可能性显著更高(p<0.001,比值比18.7,95%置信区间8.1至43.0),而抑郁症的诊断可能性显著更低(p<0.005,比值比0.133,置信区间0.031至0.558)。NPS使用者使用大麻的可能性显著更高(p<0.001,比值比4.2,置信区间2.5至7.1),开具替代阿片类药物的可能性也更高(p<0.001,比值比3.7,置信区间1.8至7.4)。
NPS的使用在年轻男性精神科住院患者中很普遍,尤其是那些患有药物性精神病的患者,并且常常与非法药物使用同时发生。